+0.090 (+3.78%)
Range 2.400 - 2.490   (3.75%)
Open 2.410
Previous Close 2.380
Buy Price 2.340
Buy Volume 14
Sell Price 2.470
Sell Volume 18
Volume 452,125
Value -
Measurement Type Value
EPS (USD) -0.105
Trailing EPS (USD) -0.099
NAV (USD) -0.694
Cash In Hand (USD) 0.104
Dividend -
Dividend Yield (%) -
PE -
Trailing PE -
Price / NAV -3.56
Price / Cash In Hand 23.704
Issued & Paid-up Shares 58,013,600
Treasury Shares -
Market Cap (M) 200.336
Par Value (USD) n.a.
Beta - 75 Days 1.409
R-Squared - 75 Days(%) 7.85
Beta - 500 Days 0.695
R-Squared - 500 Days(%) 3.76
ISIN Code -
Under CPF Investment Scheme (CPFIS) No
Index Components
Delayed prices. Updated at 08 May 2021 04:00.
Data powered by

Upcoming Events

* Stock event date based on US timezone.


Release Date 02 Aug 2021
View All Events


vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. The Company provides a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a range of human diseases, including central nervous system disorders, metabolic disorders, inflammation and cancer. The Company provides programs for the treatment of Alzheimer’s disease (AD) and type II diabetes. Its lead candidate is Azeliragon (TTP488) and its type II diabetes drug candidates include Glucokinase Activator (TTP399) and GLP-1r Agonist (TTP273). The Company also offers products for the prevention of muscle weakness and the treatment of inflammatory disorders, which include HPP593, HPP737 and HPP971. The Company utilizes TTP Translational Technology to discover small molecule therapeutics for diseases and to validate biological pathways and targets.

Loading Chart...